Connaught Labs
Executive Summary
Licenses worldwide rights to future Lyme Disease vaccines and diagnostics via recombinant antigen technology from Symbicom AB. The Swedish firm has cloned and expressed the OspA antigen, which is believed to be the primary antigen required to confer protection against the apirochete that causes Lyme Disease.